Business Context and Reporting Period
Immatics N.V. filed this Form 6-K on June 2, 2025, to disclose expanded data from its ongoing Phase 1b clinical trial of IMA203, a PRAME cell therapy. The data cutoff was April 7, 2025. The trial focuses on heavily pretreated patients with metastatic melanoma, including cutaneous, uveal, mucosal, and unknown primary subtypes.
Key Clinical Metrics and Financial Status
Clinical Efficacy (Melanoma Effic Population, n=33):
- Confirmed Objective Response Rate (cORR): 56% (18/32 evaluable patients).
- Objective Response Rate (ORR): 64% (21/33 patients).
- Disease Control Rate (Week 6): 91% (30/33 patients).
- Median Duration of Response: 12.1 months (range 1.8+ to 32.6+ months).
- Median Progression-Free Survival (PFS): 6.1 months.
- Median Overall Survival (OS): 15.9 months.
- Survival Rates: 53% PFS at 6 months; 61% OS at 12 months.
Safety Profile (Safety Population, n=74):
- Cytokine Release Syndrome (CRS): Mostly mild to moderate (Grade 1: 37%, Grade 2: 47%, Grade 3: 11%, Grade 4: 0%).
- Neurotoxicity (ICANS): Infrequent and manageable (Grade 1: 5%, Grade 2: 4%, Grade 3: 4%, Grade 4: 0%).
- Severe Events: No Grade 5 IMA203-related adverse events were observed.
Manufacturing: Products are manufactured from patient leukapheresis within 7-8 days with a 95% success rate for QC release testing as of April 7, 2025.
Financial Metrics: The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Subgroup Analysis
The filing provides a breakdown of efficacy by melanoma subtype:
- Cutaneous Melanoma (n=14): cORR of 50%; Median PFS of 6.0 months; Median OS of 13.9 months.
- Uveal Melanoma (n=16): cORR of 67%; Median PFS of 8.5 months; Median OS of 16.2 months.
Translational data indicated that even patients classified as having progressive disease under RECIST 1.1 criteria experienced shrinkage of individual lesions, including difficult-to-treat metastases in the liver, lung, and abdomen.
Outlook, Risks, and Management Commentary
Future Trials: IMA203 is currently being evaluated in two ongoing trials: the Phase 1b expansion and the SUPRAME Phase 3 trial for previously treated advanced or metastatic cutaneous melanoma. SUPRAME is planned for over 50 sites in North America and Europe.
Risks and Contingencies: The primary risks identified are treatment-emergent adverse events, specifically cytopenias associated with lymphodepletion, CRS, and ICANS. However, the filing notes these were generally manageable and no fatal (Grade 5) events occurred in the safety population.
Management Commentary: The data supports the tolerability profile and anti-tumor activity of IMA203 in heavily pretreated populations, with durable responses observed.
Key Facts for Investor Verification
- Verify the enrollment status and timeline for the SUPRAME Phase 3 trial.
- Confirm the long-term durability of response beyond the current median follow-up of 13.4 to 16.7 months.
- Monitor the manufacturing success rate and scalability as the company moves toward Phase 3.
- Review the company's cash runway and capital requirements, as this filing contains no financial data.
- Assess the regulatory pathway for IMA203 based on the 56% confirmed objective response rate in this heavily pretreated cohort.